ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Esophageal Cancer - Multimodality Therapy

Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
July 1, 2014
In this randomized trial involving195 pts from 30 centers, pts underwent chemoradiotherapy followed by surgery or surgery alone for stage I or II esophageal cancer.  The median follow-up was 94 months.  80% of pts had clinical stage II disease.  R0 resection rate and 3-year survival were similar between the groups.  Induction therapy was associated w
A Systematic Review of the Predictive Value of 18FDG-PET in Esophageal and Esophagogastric Junction Cancer After Neoadjuvant Chemoradiation on the Survival Outcome Stratification
May 27, 2014
This metanalysis identified 26 eligible studies that assess the predictive value of PET for survival after induction therapy.  Complete metabolic response was associated with a 50% decrease in mortality and in tumor recurrence compared to no response.   

Pages

Submit Content